Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New membrane could speed healing of eye infections

NCT ID NCT07559149

Disease control Sponsor: Gadjah Mada University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding a special amniotic membrane containing riboflavin and moxifloxacin to standard PACK-CXL therapy helps heal infected corneal ulcers faster. 32 adults with moderate-to-severe ulcers took part. The goal was to see if the membrane improves corneal healing and reduces inflammation compared to standard treatment alone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
amniotic membrane containing riboflavin and moxifloxacin
What this could lead to
If it works, this could offer a better way to treat infected corneal ulcers, speeding up healing and reducing inflammation.
What could go wrong
This is a small, early-phase trial with only 32 participants. The results may not apply to all patients, and the added membrane might not improve outcomes over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

32 people

The number who actually took part.

Started

Jul 2024

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients diagnosed with moderate-to-severe infectious corneal ulcers (bacterial or fungal origin) by the Infection and Immunology subdivision at Dr. Sardjito General Hospital, Yogyakarta * Patients scheduled to undergo Photo-Activated Chromophore Keratitis-Corneal Cross-linking (PACK-CXL) therapy * Patients aged 18 years and older * Patients willing to undergo PACK-CXL therapy * Patients capable of providing informed consent and willing to participate in the entire study protocol Exclusion Criteria: * Patients who refuse follow-up examinations (tear film collection, corneal staining, or corneal scans) after the PACK-CXL procedure * Patients with damaged or insufficient clinical specimens (e.g., tear samples) for laboratory analysis * Patients unable to commit to the follow-up schedule

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CXL are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

corneal ulcer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CXL Infected corneal ulcers

Contacts and locations

Locations

  • Dr. Sardjito General Hospital

    Sleman, Special Region of Yogyakarta, 55281, Indonesia